High precision MRI-guided radiation
ViewRay® Inc. (NASDAQ:VRAY) designs, manufactures, and markets the MRIdian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that defines the targeted tumour from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumour has received and adapt the prescription as needed.
After 9 years of clinical use, more than 29,000 patients have been treated on MRIdian. Today, 57 hospitals worldwide have built successful MRIdian programs to expand cancer care with many centers investing in additional systems to meet patient demand.
Are you the next big thing?
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!